Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs (Q36486905)

14 August 2017

0 references

Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs (English)

1 reference

14 August 2017

0 references

Chin Hur

1

0 references

author name string

Andrew T Chan

series ordinal

2

1 reference

14 August 2017

Angela C Tramontano

series ordinal

3

1 reference

14 August 2017

G Scott Gazelle

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

23 May 2006

1 reference

Annals of Pharmacotherapy

14 August 2017

1 reference

14 August 2017

40

1 reference

14 August 2017

1052-1063

1 reference

14 August 2017

6

1 reference

COX-2 inhibitors--a lesson in unexpected problems

14 August 2017

1 reference

Arthritis medicines and cardiovascular events--"house of coxibs".

21 January 2018

1 reference

Aspirin for the primary prevention of cardiovascular events: recommendation and rationale

21 January 2018

1 reference

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

21 January 2018

1 reference

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

21 January 2018

1 reference

The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review

21 January 2018

1 reference

COX-2 inhibitors--lessons in drug safety

21 January 2018

1 reference

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

21 January 2018

1 reference

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

21 January 2018

1 reference

Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip.

21 January 2018

1 reference

Celecoxib versus diclofenac in the management of osteoarthritis of the knee

21 January 2018

1 reference

Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials

21 January 2018

1 reference

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial

21 January 2018

1 reference

Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration

21 January 2018

1 reference

Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen

21 January 2018

1 reference

Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen

21 January 2018

1 reference

Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial

21 January 2018

1 reference

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

21 January 2018

1 reference

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

21 January 2018

1 reference

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial

21 January 2018

1 reference

A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis

21 January 2018

1 reference

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

21 January 2018

1 reference

Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo

21 January 2018

1 reference

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

21 January 2018

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

21 January 2018

1 reference

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

21 January 2018

1 reference

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program

21 January 2018

1 reference

Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis

21 January 2018

1 reference

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

21 January 2018

1 reference

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

21 January 2018

1 reference

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

21 January 2018

1 reference

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

21 January 2018

1 reference

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

21 January 2018

1 reference

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

Effect of ibuprofen on cardioprotective effect of aspirin

21 January 2018

1 reference

Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

21 January 2018

1 reference

Colorectal neoplasms: prospective comparison of thin-section low-dose multi-detector row CT colonography and conventional colonoscopy for detection.

21 January 2018

1 reference

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: similarities and differences.

21 January 2018

1 reference

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

21 January 2018

1 reference

Association between naproxen use and protection against acute myocardial infarction

21 January 2018

1 reference

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

21 January 2018

1 reference

COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G493

1 reference

14 August 2017

1 reference